Thomas Steger-Hartmann
Overview
Explore the profile of Thomas Steger-Hartmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corvi J, Diaz-Roussel N, Fernandez J, Ronzano F, Centeno E, Accuosto P, et al.
J Cheminform
. 2025 Feb;
17(1):15.
PMID: 39901182
Over the last few decades the pharmaceutical industry has generated a vast corpus of knowledge on the safety and efficacy of drugs. Much of this information is contained in toxicology...
2.
Steger-Hartmann T, Sanz F, Bringezu F, Soininen I
Toxicol Pathol
. 2024 Dec;
:1926233241303906.
PMID: 39665320
The virtual control group (VCG) concept was originally developed in the IMI2 project eTRANSAFE, using data of control animals which pharmaceutical companies have accrued over decades from animal toxicity studies....
3.
Gurjanov A, Vaas L, Steger-Hartmann T
ALTEX
. 2024 May;
41(4):660-665.
PMID: 38809255
Virtual control groups (VCGs) created from historical control data (HCD) can reduce the number of concurrent control group animals needed in regulatory toxicity studies by up to 25%. This study...
4.
Gurjanov A, Vieira-Vieira C, Vienenkoetter J, Vaas L, Steger-Hartmann T
Regul Toxicol Pharmacol
. 2024 Feb;
148:105592.
PMID: 38401762
Virtual control groups (VCGs) in nonclinical toxicity represent the concept of using appropriate historical control data for replacing concurrent control group animals. Historical control data collected from standardized studies can...
5.
Golden E, Allen D, Amberg A, Anger L, Baker E, Baran S, et al.
ALTEX
. 2023 Dec;
41(2):282-301.
PMID: 38043132
Historical data from control groups in animal toxicity studies are currently mainly used for comparative purposes to assess validity and robustness of study results. Due to the highly controlled environment...
6.
Steger-Hartmann T, Clark M
Toxicol Pathol
. 2023 Oct;
51(6):361-362.
PMID: 37905979
The availability of large amounts of high-quality control data from tightly controlled regulated animal safety data has created the idea to re-use these data beyond its classical applications of quality...
7.
Najjar A, Kramer N, Gardner I, Hartung T, Steger-Hartmann T
Front Pharmacol
. 2023 Aug;
14:1257423.
PMID: 37601064
No abstract available.
8.
Hilpert J, Groettrup-Wolfers E, Kosturski H, Bennett L, Barnes C, Gude K, et al.
Drugs R D
. 2023 Jul;
23(3):221-237.
PMID: 37422772
Introduction: BAY1128688 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme implicated in the pathology of endometriosis and other disorders. In vivo animal studies suggested...
9.
Sanz F, Pognan F, Steger-Hartmann T, Diaz C, Asakura S, Amberg A, et al.
Nat Rev Drug Discov
. 2023 Jun;
22(8):605-606.
PMID: 37316648
No abstract available.
10.
Steger-Hartmann T, Kreuchwig A, Wang K, Birzele F, Draganov D, Gaudio S, et al.
Drug Discov Today
. 2023 May;
28(8):103642.
PMID: 37244565
The data landscape in preclinical safety assessment is fundamentally changing because of not only emerging new data types, such as human systems biology, or real-world data (RWD) from clinical trials,...